Harrison Kordestani
Amministratore Delegato presso RICH PHARMACEUTICALS, INC.
Profilo
Harrison Kordestani is currently the Chief Executive Officer & Director at Rich Pharmaceuticals, Inc. and also holds a position as Manager-Finance, Acquisitions & Production at Arclight Films Pty Ltd.
Previously, he worked as a Compliance Officer at Geopulse Exploration, Inc.
Posizioni attive di Harrison Kordestani
Società | Posizione | Inizio |
---|---|---|
RICH PHARMACEUTICALS, INC. | Amministratore Delegato | 29/06/2021 |
Arclight Films Pty Ltd.
Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Direttore Finanziario/CFO | - |
Precedenti posizioni note di Harrison Kordestani
Società | Posizione | Fine |
---|---|---|
GEOPULSE EXPLORATION, INC. | Responsabile della Conformità | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GEOPULSE EXPLORATION, INC. | Commercial Services |
Aziende private | 2 |
---|---|
Arclight Films Pty Ltd.
Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Consumer Services |
Rich Pharmaceuticals, Inc.
Rich Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages on developing innovative therapies in oncology. It develops RP-323 for the treatment of Hodgkin’s lymphoma, Acute Myelogenous Leukemia, and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. The company was founded on August 9, 2010 and is headquartered in Beverly Hills, CA. | Health Technology |
- Borsa valori
- Insiders
- Harrison Kordestani